Centromere B Antibody Test

Your immune system is supposed to attack invaders, not your own cells. But sometimes it produces antibodies that target normal proteins inside your body. Centromere B antibody is one of these self-targeting antibodies, and when it shows up in your blood, it points toward a specific pattern of autoimmune disease that affects your blood vessels, skin, and sometimes your lungs. The reason this test matters is that these antibodies can appear years before you notice symptoms, giving you a window to catch trouble early.

This test is most strongly linked to a form of scleroderma called limited cutaneous systemic sclerosis, sometimes referred to as CREST syndrome. But it also appears in primary biliary cholangitis (a slow autoimmune attack on the bile ducts in your liver), Sjogren's syndrome, and other connective tissue diseases. A positive result does not mean you have full-blown disease today. It means your immune system has crossed a line, and you need to know where things stand.

What This Antibody Targets

Centromere B antibody (anti-CENP-B) belongs to a family called antinuclear antibodies (ANAs), which are antibodies directed against structures inside the nucleus of your own cells. Specifically, it targets a protein called CENP-B that sits at the centromere, the region of each chromosome that acts as a handle during cell division. When cells divide, the centromere is where the machinery grabs hold to pull chromosomes apart evenly. CENP-B is the dominant target, recognized by virtually all sera that test positive for anti-centromere antibodies.

Recent research shows that the immune response is actually broader than just CENP-B. Anti-centromere antibodies can target a large complex of at least 41 different centromere proteins organized into 16 subcomplexes. However, CENP-B remains the standard clinical test because it is the most reliably detected target and captures the great majority of positive cases.

Limited Cutaneous Systemic Sclerosis

The strongest disease association for this antibody is limited cutaneous systemic sclerosis (lcSSc). This is a form of scleroderma where skin thickening stays confined to the hands, forearms, feet, and face rather than spreading across the trunk. About 20 to 40% of all systemic sclerosis patients carry anti-CENP-B, but the rate climbs to over 50% in those with the limited cutaneous form. Finding this antibody early helps predict a disease course that is generally milder on the skin side but carries its own specific risks.

Patients who are anti-CENP-B positive tend to develop less lung scarring (called interstitial lung disease) than those with a different scleroderma antibody, anti-topoisomerase I (also known as anti-Scl-70). A meta-analysis comparing these groups found that anti-CENP-B positive patients with diffuse skin disease had roughly 83% lower odds of interstitial lung disease compared to anti-Scl-70 positive patients. Ten-year mortality was also lower, with about 58% lower odds of death compared to the anti-Scl-70 group.

Pulmonary Arterial Hypertension Risk

The trade-off for less lung scarring is a higher risk of pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs narrow and stiffen, forcing the right side of the heart to work harder. In an Australian cohort of 1,579 scleroderma patients, anti-centromere antibody positivity was associated with about 60% higher odds of developing PAH after adjusting for age, race, and other factors. Among those with diffuse skin disease, the odds were roughly five times higher.

A smaller prospective study found that anti-centromere antibody positivity was linked to nearly nine times the odds of a rapid rise in estimated pulmonary artery pressure over time. This means that if you test positive, screening for lung blood vessel problems is not optional. It should be part of your regular monitoring, even if your skin symptoms are mild.

Primary Biliary Cholangitis

About 40% of people with primary biliary cholangitis (PBC), an autoimmune disease that slowly destroys the small bile ducts in the liver, test positive for anti-centromere antibodies. When anti-CENP-B shows up in someone with PBC, it strongly predicts that they also have or will develop features of systemic sclerosis. One study found that the presence of anti-centromere antibodies in PBC patients predicted coexisting scleroderma with odds roughly 24 times higher than PBC patients without the antibody.

Other Autoimmune Associations

Anti-CENP-B also appears in Sjogren's syndrome, where it has been linked to Raynaud's phenomenon (episodes of fingers or toes turning white or blue in response to cold or stress) and heart involvement. In systemic lupus, the antibody defines a distinct subset of patients who tend to be older, have less kidney involvement, and show more Raynaud's symptoms. In one series of anti-centromere positive patients, about 30% had conditions other than scleroderma, including lupus, rheumatoid arthritis, and isolated Raynaud's phenomenon.

Diagnostic Performance

This antibody is highly specific but only moderately sensitive. That means a positive result is very likely to be real, but a negative result does not rule out disease. Across multiple studies, specificity for systemic sclerosis runs between 88% and 99%, while sensitivity sits at 29 to 33% for scleroderma overall and rises to about 57% for limited cutaneous disease specifically. Fewer than 1% of healthy controls without autoimmune disease test positive.

One practical consideration: the testing method matters. ELISA testing for CENP-B detects positive results in about 58% of scleroderma patients, compared to 35% by the older immunofluorescence method. The two approaches agree well overall, but ELISA can catch cases that immunofluorescence misses. If your clinical picture strongly suggests scleroderma and your initial ANA screen is negative, specific CENP-B ELISA testing may still be worthwhile, since roughly 24% of patients with positive anti-centromere antibodies by specific testing have a negative standard ANA.

Predicting Disease Progression

For people with very early signs of possible scleroderma, such as Raynaud's phenomenon with abnormal nail-fold capillaries (tiny blood vessels at the base of your fingernails that can be viewed under magnification), the level of anti-centromere antibody helps predict what comes next. In a study of 625 patients, higher baseline antibody levels were associated with more than four times the odds of progressing from very early disease to definite systemic sclerosis. About 42% of those with early-stage disease progressed within five years.

Scleroderma-specific antibodies tend to be mutually exclusive. It is very rare for a patient to carry both anti-CENP-B and anti-Scl-70 at the same time. In one large cohort, only 3 out of 670 tested patients had both. This means the antibody pattern acts as a fork in the road: anti-CENP-B points toward limited skin disease with pulmonary hypertension risk, while anti-Scl-70 points toward diffuse skin disease with lung scarring risk. Knowing which path you are on shapes everything from monitoring to treatment.

Reference Ranges

Anti-CENP-B is reported as positive or negative, sometimes with a numerical index value. This is not a biomarker with graded "optimal" and "borderline" tiers the way cholesterol or blood sugar works. The key question is whether the antibody is present at all, and if so, how strongly.

Different labs use different assay platforms, so the numerical cutoff for "positive" varies. Always interpret your result using the reference range provided by the specific lab that processed your sample. The antibody shows a distinctive bimodal distribution: when it is present, it tends to be present at high levels, which is one reason the test works well for diagnosis.

Ethnic Differences

Scleroderma autoantibody patterns vary significantly by ethnicity. In one study comparing Caucasian and African-American patients, anti-centromere antibodies were found only in Caucasian patients (17%) and were absent in African-Americans. This does not mean the test is useless in non-Caucasian populations, but it does mean that a negative anti-CENP-B result in an African-American patient with suspected scleroderma should prompt testing for other scleroderma-specific antibodies, which may be more common in that population.

When Results Can Be Misleading

Unlike many blood tests, anti-CENP-B results are not affected by fasting, time of day, exercise, or acute illness. The antibody is a stable immunological marker, not a dynamic measure that fluctuates with your daily activities. This makes it one of the more reliable tests to interpret from a single draw.

Two situations can produce misleading results. First, if you are receiving intravenous immunoglobulin (IVIG) therapy, the pooled antibodies from blood donors can include anti-centromere antibodies, producing a false positive that reflects the donor pool, not your own immune system. Second, certain cases of drug-induced lupus have been reported to produce anti-centromere antibodies that resolve when the offending medication is stopped. If you are on IVIG or have recently started a new medication and test positive, your doctor should consider these possibilities.

Weakly positive results near the test cutoff are less reproducible between different assay kits. If your result is borderline, retesting with the same lab and method is reasonable before drawing conclusions.

Tracking Your Trend

For most people, a single clearly positive or clearly negative result is sufficient to inform the next steps. Anti-centromere antibodies are remarkably stable over time: in one large study, 78.4% of patients had unchanged results on repeat testing. Once you test positive, the antibody typically remains positive for life regardless of treatment.

Where serial tracking adds value is in the early, uncertain phase of disease. Higher and rising antibody titers predict progression from early Raynaud's with suspicious features to definite systemic sclerosis. If you have tested positive and are being monitored for possible early scleroderma, retesting every 6 to 12 months, alongside clinical assessments like pulmonary function tests and echocardiography, helps build a picture of where your disease is heading. The titer trend, combined with physical findings and other lab results, is more informative than any single number in isolation.

If your initial result is negative but your symptoms evolve, retesting may also make sense. ELISA-based CENP-B testing can detect positivity that was missed by standard ANA immunofluorescence, so switching methods rather than simply repeating the same test may be more productive.